U.S. markets closed

Petros Pharmaceuticals, Inc. (PTPI)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.5100-0.0200 (-1.31%)
At close: 04:00PM EDT
1.5900 +0.08 (+5.30%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.5300
Bid1.5100 x 2200
Ask1.7300 x 800
Day's Range1.5000 - 1.5765
52 Week Range0.9170 - 9.5400
Avg. Volume355,841
Market Cap3.191M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-11.2300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PTPI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Petros Pharmaceuticals, Inc.
    Daily – Vickers Top Insider Picks for 09/21/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more

    Petros Pharmaceuticals Provides Letter to Shareholders

    Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders:


    Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.


    Petros Pharmaceuticals Announces Capital Raise of $15 Million

    Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the over the counter (OTC) pathway, today announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction (ED) drug, STENDRA, to non-prescription OTC status.